Literature DB >> 10411990

Convulsant actions of the neurosteroid pregnenolone sulfate in mice.

T G Kokate1, K N Juhng, R D Kirkby, J Llamas, S Yamaguchi, M A Rogawski.   

Abstract

Pregnenolone sulfate (PS) is an endogenous neurosteroid known to antagonize GABA(A) receptor-mediated inhibitory responses and potentiate NMDA receptor-mediated excitatory responses in vitro. To assess the actions of the steroid as a modulator of seizure susceptibility in vivo, PS (30-300 nmol) was administered intracerebroventricularly in mice. At doses of 50 to 150 nmol, PS elicited seizures characterized by head jerks, rearing and falling, severe forelimb and hindlimb clonus, opisthotonos and explosive running. The seizures increased in severity and frequency with time and eventually progressed to status epilepticus, tonic hindlimb extension and death. The doses producing convulsions in 50% (CD(50)) and 97% (CD(97)) of animals were 92 and 205 nmol, respectively. A subconvulsant dose of PS (50 nmol) significantly increased the convulsant potencies of systemically administered pentylenetetrazol (30-50 mg/kg) and NMDA (50-100 mg/kg). Systemically administered PS at doses as high as 100 mg/kg failed to induce seizures or alter the convulsant potencies of pentylenetetrazol and NMDA. Protection against PS (205 nmol)-induced seizures and lethality was conferred by the GABA(A) receptor positive allosteric modulators clonazepam and allopregnanolone, and by the NMDA receptor antagonists dizocilpine and (R)-CPP. The overall pharmacological profile suggests that the convulsant actions of PS are mediated predominantly via its effects on GABA(A) receptors, and also possibly by effects on NMDA receptors. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411990     DOI: 10.1016/s0006-8993(99)01287-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

1.  Insight into Molecular Mechanisms of Catamenial Epilepsy.

Authors:  Helen E. Scharfman
Journal:  Epilepsy Curr       Date:  2003-05       Impact factor: 7.500

Review 2.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

3.  Neurosteroidal modulation of in vitro epileptiform activity is enhanced in pilocarpine-treated epileptic rats.

Authors:  Zahra Shiri; Rochelle Herrington; Maxime Lévesque; Massimo Avoli
Journal:  Neurobiol Dis       Date:  2015-03-24       Impact factor: 5.996

Review 4.  Sex differences in the anticonvulsant activity of neurosteroids.

Authors:  Doodipala Samba Reddy
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 5.  Treatments for seizures in catamenial (menstrual-related) epilepsy.

Authors:  Melissa J Maguire; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2019-10-14

6.  Diminished allopregnanolone enhancement of GABA(A) receptor currents in a rat model of chronic temporal lobe epilepsy.

Authors:  Z Mtchedlishvili; E H Bertram; J Kapur
Journal:  J Physiol       Date:  2001-12-01       Impact factor: 5.182

Review 7.  Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability.

Authors:  Chase Matthew Carver; Doodipala Samba Reddy
Journal:  Psychopharmacology (Berl)       Date:  2013-09-27       Impact factor: 4.530

8.  Allopregnanolone potentiates the glutamate-mediated seizures induced by 4-aminopyridine in rat hippocampus in vivo.

Authors:  Patricia Salazar; Ricardo Tapia
Journal:  Neurochem Res       Date:  2011-11-12       Impact factor: 3.996

Review 9.  Neurosteroids and their role in sex-specific epilepsies.

Authors:  Doodipala Samba Reddy
Journal:  Neurobiol Dis       Date:  2014-06-21       Impact factor: 5.996

Review 10.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.